Yu Jingbo, Gayle Julie, Rosenthal Ning, Brown Harold, Braunstein Evan, Pemmaraju Naveen
Incyte Corporation, Health Economics and Outcomes, Wilmington, DE 19803, United States.
PINC AI™ Applied Sciences, Premier Inc., Charlotte, NC 28277, United States.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyaf001.
Healthcare resource utilization (HCRU) and costs are often elevated in patients with polycythemia vera (PV), and this patient population has an increased risk of developing thromboembolic events (TEs). This study describes HCRU, costs, and mortality during TE-related hospitalizations among patients with PV in a contemporary real-world setting in the United States.
This retrospective cohort study included adult inpatients with PV and TE discharged from 623 hospitals between January 1, 2017, and June 30, 2020 with a 2-year follow-up period after the first TE-related (index) hospitalization. Data were abstracted from the PINC AI Healthcare database, which includes 25% of US inpatient discharges.
Among 3494 patients (index TE: arterial, 69.1%; venous, 27.1%; both, 3.7%), mean (SD) age was 70.7 (14) years, and most patients were male (58.6%), White (81.2%), with Medicare insurance (72.6%). Mean (SD) Charlson Comorbidity Index score was 3.2 (2.3). Mean total hospitalization costs were $24 403 during the index hospitalization (mean [SD] hospital length of stay [LOS], 7 [9] days). A third (n = 1150) of patients were admitted to the intensive care unit (mean cost, $29 342; mean [SD] LOS, 5 [7] days). During 30 days and 2 years of follow-up, the TE-related readmission rate was 6.4% and 20.0%, respectively. All-cause mortality was 6.2% during index hospitalization; an additional 4.7% occurred during the 2-year follow-up period.
Among patients with PV and TE, inpatient hospitalization HCRU, costs, and mortality were substantial. These findings highlight the importance of preventing TEs in the management of PV.
真性红细胞增多症（PV）患者的医疗资源利用（HCRU）和成本通常较高，且该患者群体发生血栓栓塞事件（TE）的风险增加。本研究描述了美国当代真实世界环境中PV患者与TE相关住院期间的HCRU、成本和死亡率。
这项回顾性队列研究纳入了2017年1月1日至2020年6月30日期间从623家医院出院的成年PV和TE住院患者，并在首次与TE相关（索引）住院后进行了2年的随访。数据从PINC AI医疗数据库中提取，该数据库包括美国25%的住院出院病例。
在3494例患者中（索引TE：动脉型，69.1%；静脉型，27.1%；两者皆有，3.7%），平均（标准差）年龄为70.7（14）岁，大多数患者为男性（58.6%），白人（81.2%），拥有医疗保险（72.6%）。平均（标准差）Charlson合并症指数评分为3.·2（2.3）。索引住院期间的平均总住院成本为24403美元（平均[标准差]住院时长[LOS]，7[9]天）。三分之一（n = 1·150）的患者入住重症监护病房（平均成本，29342美元；平均[标准差]LOS，5[7]天）。在30天和2年的随访期间，与TE相关的再入院率分别为6.4%和20.0%。索引住院期间的全因死亡率为6.2%；在2年随访期间又有4.7%的患者死亡。
在PV和TE患者中，住院期间的HCRU、成本和死亡率都很高。这些发现凸显了在PV管理中预防TE的重要性。
